Who knows how high this will end up . AML trial should give it a kick up to that 29c. Hopefully i don't sell out too cheap.
AML is a type of cancer that affects the blood and bone marrow » » Patient cannot produce normal blood cells .
Blood cells cannot function properly nor fight disease .
Progresses very quickly;
5 year survival only 25%
More common in adults over 60 years old, so the market is growing rapidly in developed economies » 50% increase in incidence since 2013 in the US alone!
After initial chemo, most patients relapse .
There are poor options for relapsing and refractory AML patients. Treatment has barely changed in ~40 years!
PTX200’s approach mirrors other current successful development approaches in AML of targeted therapies complementing a “backbone” of chemo .
PTX200’s compelling efficacy signals has attracted interest of renowned clinicians and investors.
